Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
about
Clinical trials of combined molecular targeted therapy and locoregional therapy in hepatocellular carcinoma: past, present, and futureAbrus agglutinin suppresses human hepatocellular carcinoma in vitro and in vivo by inducing caspase-mediated cell death.Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE StudyTLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progressionCurrent management of hepatocellular carcinoma: an Eastern perspective.Efficacy of radioembolization according to tumor morphology and portal vein thrombosis in intermediate-advanced hepatocellular carcinoma.A patient who has survived for a long period with repeated radiotherapies for multifocal extrahepatic metastases from hepatocellular carcinoma.Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with SorafenibInfiltrative Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With a Single High-Dose Y90 Radioembolization and Subsequent Liver Transplantation Without a Recurrence.Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis.Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
P2860
Q27013055-4514E175-BF4F-400D-9AB0-8A47A577235DQ33861908-BC5A0C7A-3B26-46AA-B559-A6616BA93DD8Q35025403-F6200299-FB4B-403E-A8EC-1C28975D818FQ36404761-DE222E31-FB5E-4E69-B07B-0E83E79842C6Q36413746-505FEEA8-1F00-4295-9CAC-C3FE11CC8907Q38410816-A9DFD821-FC61-4856-A104-7947E73201EBQ38953448-F8B3041A-58EB-418D-9E5A-910062BEF0B6Q41903601-3EB1C7A1-D8EB-4757-9934-455B205D253BQ42343440-80833A83-7154-462F-9C53-89E453C4E44CQ46851061-887F62CD-A567-409E-A94E-92E86F8EF18AQ52604161-300CD53A-CB44-45D0-8951-6CDA4A456031Q53161133-AF15D1AC-1A7C-4D03-9823-C9CEBDF82071Q53324924-3E9CD8C1-ABA3-481D-B6EC-8858DFACA3D4
P2860
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Survival of patients with adva ...... fenib versus other treatments.
@en
Survival of patients with adva ...... fenib versus other treatments.
@nl
type
label
Survival of patients with adva ...... fenib versus other treatments.
@en
Survival of patients with adva ...... fenib versus other treatments.
@nl
prefLabel
Survival of patients with adva ...... fenib versus other treatments.
@en
Survival of patients with adva ...... fenib versus other treatments.
@nl
P2093
P2860
P1476
Survival of patients with adva ...... fenib versus other treatments.
@en
P2093
Byung-Ho Nam
Chang-Min Kim
Hwi Young Kim
Hyun Beom Kim
Hyun Keun Kim
Joong-Won Park
Tae Hyun Kim
P2860
P304
P356
10.1111/J.1440-1746.2011.06751.X
P50
P577
2011-11-01T00:00:00Z